Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may be effective agents for the treatment of EMs, as they have the potential to control the symptoms associated with EMs in cases where no therapeutic response was achieved with an initial pharmacological intervention (Soares et al., 2012; Peitsidis et al., 2023). The gene discussed is CYP19A1; the disease is eosinophilia-myalgia syndrome.